

AXE 4 : *Evaluation toxicologique et toxicité potentielle à l'échelle individuelle et populationnelle*



1) Evaluation toxicologique

- Toxines émergentes (palytoxine et congénères) : études de toxicité par voie orale et par inhalation
- Caractérisation du mécanisme d'action par méthodes non-ciblées
- Investigation des TEFs
- Imines cycliques : affinité pour récepteurs nicotiques; implication dans maladies neurodégénératives; recherche de nouvelles substances d'intérêt
- Effets toxiques des toxines lipophiles à l'aide de tests in vitro multi-paramétriques
- Etude de la métabolisation des toxines
- Effets combinés des toxines

AXE 4 : *Evaluation toxicologique et toxicité potentielle à l'échelle individuelle et populationnelle*



2) Modélisation mathématique du risque potentiel pour la population humaine dans certaines situations théoriques

- Tester l'impact de différentes situations de contamination ou de différentes mesures de gestion
- Tester les chaînes de causalité en fonction de la contamination (dose, exposition à court ou long terme,...)

AXE 4 : *Evaluation toxicologique et toxicité potentielle à l'échelle individuelle et populationnelle*



Anses laboratoire de Fougères, unité Toxicologie des contaminants
Anses, Direction de l'évaluation des risques de Maisons-Alfort
CNRS, Gif/Yvette

- Acute toxicology with lipophilic toxins
- Intestinal absorption kinetics
- Mechanism of action
- Mixtures
- Development of new tools for toxicity prediction or detection of compounds

Research activity per scientist

Valérie Fessard: Toxicology

Ludovic Le Hégarat: Genotoxicity, development of cell models

Kevin Hogeveen : In vitro High Content Screening

Antoine Huguet: Intestinal absorption kinetics, mechanism of action


Pierre-Jean Ferron: In vitro High Content Screening, mixtures




Models

Human intestinal cells


Caco2



HT29-MTX




HIEC




Human liver cells

HepG2




HepaRG



Human lung cells

A549



En cours

Thèse CLIMPHYC : Nouvelles approches in vitro pour l'étude des effets toxiques des phycotoxines lipophiles, seules ou combinées, susceptibles d'émerger suite à un dérèglement climatique
Collaboration avec INRA (R. Rahmani), université Sherbrooke (Canada), JF Beaulieu)

Projet DGAI/DGS PINNA : Etude de pinnatoxines en lien avec l'espèce *Vulcanodinium rugosum*
Intestinal barrier kinetics and effects on intestinal cell lines of pinnatoxin G and A and mussel extracts;
Collaboration avec CNRS Gif/Yvette (R. Araoz)

Thèse Palytoxine/ovatoxines:

Various effects on human intestinal, liver and pulmonary cell lines;
Collaboration avec IRTA Tarragone (L. Solino, J. Diogène)

Etude brevéttoxines:

Intestinal absorption kinetics of brevetoxins and metabolites
Collaboration avec NOAA (J. Ramsdell)


En attente de réponse

Thèse COMEBACK : Effect of CO-exposure to MarinE lipophilic Biotoxins on the intestinal barrier, bioActivation and identification of molecular modes of aCtions
Intestinal barrier and metabolism of lipophilic phycotoxins alone and in mixtures
Co financement Anses/BfR, collaboration avec équipe A. Lampen (Department of Food Safety, Federal Institute for Risk Assessment)


Thèse sur projet ANR CARISMATIG : Réactivité chimique et détection des ciguatoxines et maitotoxines dans des cultures de microalgues et dans des poissons

Collaboration avec l'Ifremer Nantes; Mise en place du test Neuro2A pour la détection des ciguatoxines


Effet toxiques sur modèles cellulaires humains intestinaux





Passage de la barrière intestinale à l'aide d'un modèle *in vitro*



Approche intégrée bio-analytique (EDA)



Mécanisme d'action?



Effet toxiques sur modèles cellulaires humains hépatiques
Métabolisation




CNRS-Gif / Equipe MOLGO: Une approche multi-échelle pour déterminer le mécanisme d'action de phycotoxines neurotoxiques



→ Septembre 2014

In-vivo

Organisme




Développement de l'embryon de poulet
(A. COUESNON)

Force de préhension
E. BENOIT

Excitabilité neuromusculaire *in-vivo*
(E. BENOIT)

Cell/Tissue




Imagerie : jonction neuromusculaire/ électrophysiologie : fibre nerveuse
[A. COUESNON (m. confocale) E. BENOIT (électrophysiologie)]

Ex-vivo

Electrophysiologie de la jonction neuromusculaire
(J. MOLGO, A. COUESNON)

Molécule



Pharmacologie des récepteurs nicotiniques de l'acétylcholine. Potentiel impose à double microélectrodes (R. ARAOZ)

Purification et caractérisation physico-chimique de neurotoxines
[B. NGUYEN (conozeptides) R. ARAOZ (alkaoïdes)]







Toxines, Récepteurs et Canaux

CEA/ibiTecS/SIMOPRO – D. Servent



Natural toxins as tools to study receptors/channels function and source of imaging or therapeutic agents



Identification of new toxins active on receptors and channels

- Screening of venoms and natural sources on receptors and channels
 - Venoms and toxins purification
- High throughput solid phase peptide synthesis and refolding of reticulated peptides (10-70 aa)




Imaging, therapeutic applications

- Patents of toxins according to their pharmacological properties
 - Biodistribution of radioactive toxins
- Collaborations to explore ex-vivo and in-vivo the therapeutic potentials of toxins

Structure/Function studies

- Pharmacological characterization of toxin-receptor interaction (radioactive binding assays, fluorescent/HTRF experiments)
- Mutational analysis
- Modeling of toxin/receptor complexes



Toxins Engineering

- Synthesis of non-natural, chimeric and labelled toxins (fluorescent, radioactive derivatives) with new functional properties
- Structure-based/phage display/phylogenetic engineering






CNRS/TRIPSYN/NED - CEA/ibiTecS/SIMOPRO : HIGHLIGHTS




Identification of the first toxin active on the Vasopressin V2 receptor with potential effect on kidney disease (patented in 2012)



Pharmacological, structural characterization of toxins interacting with mAChRs and engineering to modify their functional property (Marquer et al. JBC. 2011; Fruchart et al. PlosOne, 2012)



Elucidation of the mechanism of action of gymnodimine A, 13-desmethyl spirolide C and pinnatoxins A and G. Development of functional detection methods (patented in 2012).





CNRS/TRIPSYN/NED - CEA/ibiTecS/SIMOPRO: PROJETS (Past/ Present/ Futur)



European & International Grants



VENOMICS (FP7, 8 partners) (2012-2016): High-throughput peptidomics and transcriptomics of animal venoms for discovery of novel therapeutic peptides. Coordinator of the project



NIH Subaward grant KK1036 # 056280 (responsible: A. ZAKARIAN). Source: US National Institutes of Health (NIH) program # 3R01 GM077379-02S1 (01/8/2009 - 31/05/2013).



PHARMATLANTIC : # 2009-1/117 (coordinator: L.M. BOTANA), Source: EU's Atlantic Area Programme (01/04/2010 - 01/12/2013) [http:// www.pharmatlantic.org](http://www.pharmatlantic.org).



ATLANTOX : # STC-CP 2008-1-555612 (coordinator: L.M. BOTANA). Source: EU's Atlantic Area Programme (01/01/2009 - 31/12/2011; prolonged to 01/12/2013)

National Grants



AQUANEUROTOX : # ANR-12-ASTR-0037-01 (coordinator: J. MOLGÓ). Source: Agence Nationale de la Recherche (01/2/2013 - 31/1/2016).



**ANR RPIB (2012-2015), VenomPicoScreen
ANR BiotechS (2010-2013), PeptoMed**



ARISTOCYA : # 052805 (coordinator: D. LAURENT). Source: Agence Nationale de la Recherche. (01/12/2008 - 30/11/2012).



NEUROSPIROIMINE : # 07-PCVI-0008-01 (coordinator: J. MOLGÓ). Source: Agence Nationale de la Recherche (29/11/2007 - 28/11/2010).

Submitted Grants



Contrat ANSES: Appels à projets de recherche sur la santé environnement et la santé au travail. Coordinateur : E. BENOIT. Titre : NeuroTox - Etudes de neurotoxines marines émergentes présentant un risque potentiel pour la santé publique.



ANR: Appel à projets "Grands défis sociétaux: Santé et bien-être". Coordinateur: D. JOSEPH. Titre: Rational Design and Synthesis of Scaffolds targeting Nicotinic Receptors by Atomic Resolution.

-**Main Activity:** health risk assessment
(for human consumers)

-**Research activity (linked to GdR) :**

- review of toxicity data (*in vitro*, *in vivo*, humans)
- analysis of occurrence data
- dietary exposure analysis
- quantitative risk assessment/management (modeling)
- scientific support to risk manager and regulation (FR, EU, Codex)



Educational background & Research activity per scientist

Anne Thébault: PhD in epidemiology & biomathematics, doctor in veterinary medicine ; marine biology, biostatistics, math. modeling

Nathalie Arnich: PhD in toxicology, educ. in biology & marine biology ; risk assessment associated with contaminants in food, toxicity of biotoxins

Projects in progress

- ANR « ACCUTOX »: Physiological and genetic determinism, risk assessment and social issues of paralytic toxins (PST) accumulation by oyster *Crassostrea gigas* (2013-2017)
- ANR « FISH-PARASITES »: parasites in fish - hazard identification, impact, and researches to define an efficient strategy of prevention (2010-2014)

Requests from French Ministries (linked to GdR) in progress

- update the strategy for setting « at-risk » periods for lipophilic phycotoxins
- review the « vigilance » system for lipophilic phycotoxins in place in France since 2010
- ciguatoxins/sharks/Réunion island
- efficiency of seawater treatments for on-land shellfish ponds

Past & Present research projects

- 4 ANR; 3 linked to marine biology : FISH-PARASITES, COQENPATH, ACCUTOX
- 5 European projects; 2 linked to marine biology

International peer-reviewed publications: 19 (Anne) + 12 (Nathalie)

International conferences: oral/poster at ICMSS (all since 2004), HAB 2010
scientific & edition committee of ICMSS-2009 in France

Figure représentative de l'équipe

1. Hazard identification

What are the potential adverse health effects? One or several compounds?

2. Hazard characterization

What are the nature and the severity of the health effects at different exposure levels (dose-response)?

3. Exposure assessment

What is the amount of the contaminant to which people were exposed or could be exposed?

4. Risk characterization

What is the health risk caused by the contaminant in the exposed population (likelihood and severity of an adverse effect)?

